Market Overview

Endologix Appoints John D. Zehren as Chief Commercial Officer


Endologix, Inc. (NASDAQ:ELGX) ("Endologix" or the "Company"), a
developer and marketer of innovative treatments for aortic disorders,
today announced that it has appointed John D. Zehren as the Company's
Chief Commercial Officer, effective as of January 7, 2019 (the
"Effective Date").

Mr. Zehren brings to Endologix more than twenty years of commercial,
sales and marketing, and business development experience in the medical
device industry. Most recently, he served as Vice President of Sales,
Americas at Medtronic Neurovascular and was a Senior Member of the
company's Neurovascular Management Board. While at Medtronic, he
developed and implemented a strategic commercial plan to double revenue
in five years. Prior to that, he spent five years as Vice President of
Sales at Covidien and ev3. Earlier in his distinguished career, Mr.
Zehren spent over a decade at Edwards Lifesciences, the last four years
of which were in the role of Vice President of Sales and Marketing.

John Onopchenko, Chief Executive Officer of Endologix, Inc., commented,
"We are proud to welcome John, an accomplished commercial medical device
leader, to our executive team. He has demonstrated a strong track record
of achievement, consistently implementing successful commercial
strategies that resulted in impressive growth, share gains, and customer
loyalty. We believe John will play a critical role in strengthening and
extending Endologix's customer partnerships and commercial execution,
while leading the Company's global go-to-market strategy for our AFX2,
Ovation, and Nellix platforms."

Mr. Zehren added, "I'm excited to join an organization that has driven
so much innovation in the cardiovascular segment and believe that we
have an excellent opportunity to strengthen our customer partnerships
and secure increased market share and procedural growth around the
globe. I look forward to working with the Endologix team to drive
commercial excellence and bring our differentiated, life-saving
technology to more patients in need."

Mr. Zehren earned his Bachelor of Arts in Biology from College of St.
Thomas in Minnesota.

The Company has also announced that in connection with Mr. Zehren's
employment by Endologix, he will receive equity awards under the
Company's 2017 Inducement Stock Incentive Plan, consisting of 300,000
stock options ("Option") and 200,000 restricted stock units (RSUs) The
awards were approved by the Company's Compensation Committee, which is
comprised of independent directors, on December 3, 2018, as an
inducement material to the Mr. Zehren's entry into employment with the
Company, as permitted under NASDAQ Listing Rule 5635(c)(4). The Options
will be priced as of the Effective Date and will vest over a three-year
period. One third of the Options shall vest and become exercisable upon
his completion of one year of service. The balance of the Options shall
vest and become exercisable in successive, equal, monthly installments
upon Mr. Zehren's completion of the next twenty four months of service,
measured from the first anniversary of the grant date. The RSUs will
vest as to one-third of the underlying shares on each anniversary of the
Effective Date such that the shares will vest in full three years from
the Effective Date.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments
for aortic disorders. The Company's focus is endovascular stent grafts
for the treatment of abdominal aortic aneurysms (AAA). AAA is a
weakening of the wall of the aorta, the largest artery in the body,
resulting in a balloon-like enlargement. Once AAA develops, it continues
to enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 80%, making it a leading cause of death in the United
States. For more information, visit

Cautions Regarding Forward-Looking Statements

Except for historical information contained herein, this press
release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements generally can be identified by the use of words such as
"anticipate," "expect," "could," "may," "will," "believe," "estimate,"
"forecast," "goal," "project," "continue," "outlook," "guidance,"
"future," other words of similar meaning and the use of future dates.
Forward-looking statements used in this press release include, but are
not limited to, statements regarding the anticipated commencement (and
commensurate benefits) of Mr. Zehren's employment with Endologix
(including anticipated strengthening and extension of Endologix's
customer partnerships and commercial execution, and securing increased
market share and procedural growth), the accuracy of which are
necessarily subject to risks and uncertainties that may cause
Endologix's actual results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ materially and
adversely from anticipated results include continued market acceptance,
hiring, integration and retention of Mr. Zehren, risks regarding Quality
systems operations and outcome of third party audits of such systems,
endorsement and use of Endologix's products, risks associated with the
manufacturing of Endologix's products, the success of clinical trials
relating to Endologix's products, product research and development
efforts, uncertainty in the process of obtaining and maintaining U.S.
FDA and other regulatory approvals for Endologix's products, Endologix's
ability to access equity and debt capital on acceptable terms,
Endologix's ability to enter into or maintain existing financing
arrangements on acceptable terms, risks associated with international
operations, including currency exchange rate fluctuations, Endologix's
ability to protect its intellectual property rights and proprietary
technologies, and other economic, business, competitive and regulatory
factors. Undue reliance should not be placed upon the forward-looking
statements contained in this press release, which speak only as of the
date of this press release. Endologix undertakes no obligation to update
any forward-looking statements contained in this press release to
reflect new information, events or circumstances after the date they are
made, or to reflect the occurrence of unanticipated events. Please refer
to Endologix's filings with the Securities and Exchange Commission
including its Annual Report on Form 10-K for the year ended December 31,
2017 and subsequent Quarterly Reports on Form 10-Q, for more detailed
information regarding these risks and uncertainties and other factors
that may cause actual results to differ materially from those expressed
or implied.

View Comments and Join the Discussion!